Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Status:
Terminated
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate
the efficacy and safety of brentuximab vedotin in combination with rituximab and bendamustine
for the treatment of patients with relapsed or refractory CD30-positive diffuse large B-cell
lymphoma (DLBCL) after failure of second-line salvage therapy or as second-line treatment in
patients ineligible for autologous stem cell transplant (ASCT).